Funded Startups in Plymouth
Across the 17 most recent rows, the largest disclosed round is Idrx’s $120M (2024-08-07), which substantially dwarfs the next-largest disclosed amounts ($8…
Across the 17 most recent rows, the largest disclosed round is Idrx’s $120M (2024-08-07), which substantially dwarfs the next-largest disclosed amounts ($88M for Endogenex on 2024-06-25 and $35M for Monteris Medical on 2026-03-12). Several smaller disclosed rounds cluster at the low end, with MetaModix’s $500K (2023-01-26) and Esperovax’s $1M (2023-10-03) standing far below the rest.
The geographic pattern is also concentrated around Plymouth, Minnesota: at least 10 of the 17 entries list Plymouth, Minnesota (including Monteris Medical 2026-03-12, Endogenex 2024-06-25, and Clearfield 2022-12-06), while other “Plymouth” locations appear less frequently (UK, Massachusetts, New Hampshire, and Indiana). Temporally, the window runs from 2021-04-01 (WellWay) through the most recent 2026-06-22 (HistoSonics), and “Series Unknown” is common: 7 entries use “Series Unknown,” plus 2 additional rows are “undisclosed” (HistoSonics 2026-06-22; Voices Against Violence 2023-06-21). Health care and biotechnology recur across multiple rows, with health care-related entries spanning years such as 2026, 2024, and 2022.
Most recent rounds
17 shownRelated listings
Frequently asked
Which disclosed round is the outlier in this Plymouth-focused set, and what sits just below it?
Idrx’s $120M (2024-08-07) is the only disclosed round at that level in these 17 rows, and it is followed by Endogenex’s $88M (2024-06-25) and Monteris Medical’s $35M (2026-03-12), with most remaining disclosed amounts far lower (e.g., MetaModix at $500K on 2023-01-26).
Are Plymouth entries clustered in one geography, or spread across multiple Plymouth cities/countries?
Plymouth, Minnesota is over-represented, appearing in at least 10 of 17 rows (e.g., Monteris Medical 2026-03-12, Endogenex 2024-06-25, Clearfield 2022-12-06). Other Plymouth locations exist but are less frequent: Plymouth, UK (Altilium Clean Technology 2026-04-09; Imployable 2022-04-25) plus Plymouth, Massachusetts (Idrx 2024-08-07), Plymouth, New Hampshire (Voices Against Violence 2023-06-21), and Plymouth, Indiana (SIMBA Chain 2022-02-10).
How much of the list lacks stage clarity (Series Unknown / undisclosed), and does that complicate comparing rounds?
Stage labeling is incomplete in this slice: 7 rows are marked “Series Unknown” and 2 rows are “undisclosed” (HistoSonics 2026-06-22; Voices Against Violence 2023-06-21). That means the largest-comparison view relies primarily on the disclosed rounds where amounts are provided (e.g., Idrx $120M and Clearfield $120M).
What stage mix is visible when amounts are disclosed, and do any stages appear repeatedly?
The disclosed rows include multiple “Series Unknown” entries (e.g., Altilium Clean Technology $25M on 2026-04-09; Esperovax $1M on 2023-10-03) and several “Series C” entries (Venture Med Group $28M on 2025-11-03; Laplace Interventional $22M on 2025-03-16; Endogenex $88M on 2024-06-25). Other stages appear as singletons in this view, such as Seed (Imployable $200K on 2022-04-25) and Grant (SpineThera $5M on 2022-04-26; SIMBA Chain $100K on 2022-02-10).
Which entries fall closest to the most recent dates, indicating current activity?
The newest set of rows spans 2026-06-22 through 2026-03-12, including HistoSonics (2026-06-22, undisclosed), Reprise Biomedical (2026-05-21, $2M), Altilium Clean Technology (2026-04-09, $25M), and Monteris Medical (2026-03-12, $35M). Beyond that, the next cluster of disclosed activity shows up in 2025, including Venture Med Group ($28M on 2025-11-03) and Laplace Interventional ($22M on 2025-03-16).
Is there a sector concentration, and do any sectors show notably different funding levels?
Biotechnology and health care repeatedly appear across different years (e.g., Idrx Biotechnology $120M on 2024-08-07; Endogenex Health Care $88M on 2024-06-25; Monteris Medical Health Care $35M on 2026-03-12). Meanwhile, some non-health sectors show much smaller disclosed amounts in this slice, such as MetaModix Biotechnology at $500K (2023-01-26) and SIMBA Chain Financial Services at $100K (2022-02-10), suggesting funding levels vary widely within the broader health-adjacent presence.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.